Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares Core MSCI Emerging Markets ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares Core MSCI Emerging Markets ETF trades at $77.23 (market cap $154.46B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 15.1× Globus Medical Inc. Class A Common Stock's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares Core MSCI Emerging Markets ETF for 59 Days on average.
| GMED | IEMG | |
|---|---|---|
Market Cap | $10.25B | $154.46B |
Volume | 1,059,528 | 11,412,044 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $86.00 |
52-Week Low | $58.33 | $64.72 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
IEMG trades at $80.22, down 0.51% with a bearish technical signal from moving averages. The ETF faces neutral oscillators but shows support at $79-80 levels. Recent news highlights IEMG's strong performance against peers like SCHE and VWO, with emerging markets attracting record inflows amid dollar weakness and tech sector exposure.
Outlook remains mixed: technical weakness contrasts with fundamental appeal via low-cost emerging market access and 35% trailing returns. Risks include concentration in tech, volatility, and expense ratio disadvantages versus competitors. Analyst sentiment leans cautious due to recent underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
